Clinical Report: A Systemic Problem in Metabolite Identification?

Overview

A significant misidentification of phenylacetylglutamine (PAGln) as phenylacetylglycine (PAGly) has been found in nearly half of NMR-based studies involving human urine samples over the past few decades. This persistent error raises concerns about the reliability of metabolomic data and its implications for clinical interpretations.

Background

Accurate metabolite identification is crucial for understanding metabolic pathways and their clinical relevance, especially as metabolites like PAGln are linked to various cardiovascular and neurological diseases. The propagation of misidentifications undermines the credibility of metabolomics, potentially leading to incorrect biological interpretations and clinical decisions. Addressing these errors is essential for advancing the field and ensuring the validity of research findings.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

Clinical Implications

Clinicians and researchers should be aware of the potential for misidentification in metabolomic studies, particularly those relying on NMR techniques. Ensuring accurate metabolite assignments is vital for interpreting clinical data and understanding disease mechanisms. The findings underscore the need for improved identification workflows in metabolomics to enhance the reliability of research outcomes.

Conclusion

The systematic misidentification of metabolites like PAGln poses significant challenges for the metabolomics field. Addressing these issues is essential for maintaining the integrity of research and its clinical applications.

References

1. Nicholson et al., Analytical Chemistry, 2025 -- Investigating a Systematic and Widespread Misidentification in the Metabolic Profiling Literature: Phenylacetylglutamine and Phenylacetylglycine Signal Misassignment in Proton NMR Spectra of Human and Rodent Urine
2. Giera et al., European Heart Journal, 2025 -- Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions
3. Halama et al., Archives of Toxicology, 2022 -- Utilizing Metabolic Profiling to Investigate Cellular Changes Induced by 20 Mycotoxins in HepG2 Cell Lines
4. Bujak et al., Archives of Toxicology, 2021 -- Metabolomic Profiling for Differentiating Phenotypes of Drug-Induced Liver Injury (DILI)
5. the analytical scientist — The Missing Piece in the Dark Metabolome Puzzle?
6. Archives of Toxicology — Utilizing In Silico Tools to Identify Metabolites of Emerging Psychoactive Compounds
7. The Missing Piece in the Dark Metabolome Puzzle?
8. Investigating a Systematic and Widespread Misidentification in the Metabolic Profiling Literature: Phenylacetylglutamine and Phenylacetylglycine Signal Misassignment in Proton NMR Spectra of Human and Rodent Urine | Analytical Chemistry
9. Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions | European Heart Journal | Oxford Academic
10. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology